Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 1
2003 1
2004 1
2005 1
2006 1
2007 2
2010 1
2013 1
2015 1
2019 1
2020 2
2021 1
2022 1
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
Riudavets M, Auclin E, Mosteiro M, Dempsey N, Majem M, Prelaj A, López-Castro R, Bosch-Barrera J, Pilotto S, Escalera E, Tagliamento M, Mosquera J, Zalcman G, Aboubakar Nana F, Ponce S, Albarrán-Artahona V, Dal Maso A, Spotti M, Mielgo X, Mussat E, Reyes R, Benítez JC, Lupinacci L, Duchemann B, De Giglio A, Blaquier JB, Audigier-Valette C, Scheffler M, Nadal E, Lopes G, Signorelli D, Garcia-Campelo R, Menis J, Bluthgen V, Campayo M, Recondo G, Besse B, Mezquita L, Planchard D. Riudavets M, et al. Among authors: mosteiro m. Clin Lung Cancer. 2023 Nov 22:S1525-7304(23)00242-5. doi: 10.1016/j.cllc.2023.11.007. Online ahead of print. Clin Lung Cancer. 2023. PMID: 38105153
Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network.
Mulet Margalef N, Castillo C, Mosteiro M, Pérez X, Aguilar S, Ruíz-Pace F, Gil M, Cuadra C, Ruffinelli JC, Martínez M, Losa F, Soler G, Teulé À, Castany R, Gallego R, Ruíz A, Garralda E, Élez E, Vivancos A, Tabernero J, Salazar R, Dienstmann R, Santos Vivas C. Mulet Margalef N, et al. Among authors: mosteiro m. Mol Oncol. 2023 Sep;17(9):1908-1916. doi: 10.1002/1878-0261.13444. Epub 2023 Jun 12. Mol Oncol. 2023. PMID: 37097008 Free PMC article.
Validation of a Pathological Score for the Assessment of Bronchial Biopsies in Severe Uncontrolled Asthma: Beyond Blood Eosinophils.
Cosio BG, Shafiek H, Iglesias A, Mosteiro M, Gonzalez-Piñeiro A, Rodríguez M, García-Cosío M, Busto E, Martin J, Mejías L, Benito A, López Vilaro L, Gómez C. Cosio BG, et al. Among authors: mosteiro m. Arch Bronconeumol. 2023 Aug;59(8):502-509. doi: 10.1016/j.arbres.2023.05.014. Epub 2023 Jun 1. Arch Bronconeumol. 2023. PMID: 37414638 Free article. English, Spanish.
Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centre.
Mosteiro M, Azuara D, Villatoro S, Alay A, Gausachs M, Varela M, Baixeras N, Pijuan L, Ajenjo-Bauza M, Lopez-Doriga A, Teulé Á, Solanes A, Palmero R, Brenes J, Jové M, Padrones S, Moreno V, Cordero D, Matías-Guiu X, Lázaro C, Nadal E. Mosteiro M, et al. ESMO Open. 2023 Dec;8(6):102197. doi: 10.1016/j.esmoop.2023.102197. Epub 2023 Dec 8. ESMO Open. 2023. PMID: 38070435 Free PMC article.
Asthma, Comorbidities, and Aggravating Circumstances: The GEMA-FORUM II Task Force.
Trigueros JA, Plaza V, Domínguez-Ortega J, Serrano J, Cisneros C, Padilla A, Antón Gironés M, Mosteiro M, Martínez Moragón E, Olaguíbel Rivera JM, Delgado J, García Rivero JL, Martínez Rivera C, Garrido JJ, Quirce S; GEMAFORUM Task Force. Trigueros JA, et al. Among authors: mosteiro m. J Investig Allergol Clin Immunol. 2020 Apr 24;30(2):140-143. doi: 10.18176/jiaci.0460. Epub 2019 Oct 10. J Investig Allergol Clin Immunol. 2020. PMID: 31599723 Free article. No abstract available.
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.
Riudavets M, Auclin E, Mosteiro M, Dempsey N, Majem M, Lobefaro R, López-Castro R, Bosch-Barrera J, Pilotto S, Escalera E, Tagliamento M, Mosquera J, Zalcman G, Aboubakar-Nana F, Ponce S, Dal Maso A, Spotti M, Mielgo-Rubio X, Mussat E, Reyes R, Benítez JC, Lupinacci L, Duchemann B, De Giglio A, Blaquier J, Audigier-Valette C, Scheffler M, Nadal E, Lopes G, Signorelli D, Garcia-Campelo R, Menis J, Bluthgen V, Campayo M, Recondo G, Besse B, Planchard D, Mezquita L. Riudavets M, et al. Among authors: mosteiro m. Eur J Cancer. 2022 May;167:142-148. doi: 10.1016/j.ejca.2022.02.014. Epub 2022 Mar 17. Eur J Cancer. 2022. PMID: 35307254
Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.
Nokin MJ, Darbo E, Travert C, Drogat B, Lacouture A, San José S, Cabrera N, Turcq B, Prouzet-Mauleon V, Falcone M, Villanueva A, Wang H, Herfs M, Mosteiro M, Jänne PA, Pujol JL, Maraver A, Barbacid M, Nadal E, Santamaría D, Ambrogio C. Nokin MJ, et al. Among authors: mosteiro m. JCI Insight. 2020 Aug 6;5(15):e137869. doi: 10.1172/jci.insight.137869. JCI Insight. 2020. PMID: 32759499 Free PMC article.
22 results